

# Daniel E Spratt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5254719/publications.pdf>

Version: 2024-02-01

334  
papers

13,405  
citations

31976

53  
h-index

31849

101  
g-index

338  
all docs

338  
docs citations

338  
times ranked

15091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
2	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	28.9	459
3	International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2012, 83, e597-e605.	0.8	457
4	Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers. Cancer Discovery, 2013, 3, 1245-1253.	9.4	421
5	A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy. European Urology, 2013, 64, 895-902.	1.9	334
6	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	7.1	288
7	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	12.4	276
8	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896.	7.4	252
9	Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncology, 2016, 2, 1070.	7.1	250
10	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.8	247
11	Long-term Survival and Toxicity in Patients Treated With High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 686-692.	0.8	229
12	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Network Open, 2019, 2, e188006.	5.9	221
13	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. Lancet Oncology, The, 2017, 18, e720-e730.	10.7	220
14	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	7.1	219
15	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	21.4	198
16	Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis. Journal of Oncology, 2011, 2011, 1-13.	1.3	191
17	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	10.7	182
18	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017, 35, 1991-1998.	1.6	176

#	ARTICLE	IF	CITATIONS
19	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA - Journal of the American Medical Association, 2019, 321, 704.	7.4	168
20	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	1.6	162
21	Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. European Urology, 2013, 63, 709-716.	1.9	152
22	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 659-665.	1.2	149
23	The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy. European Urology, 2015, 67, 1009-1016.	1.9	147
24	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	6.3	142
25	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
26	Targeted Nanoparticles That Deliver a Sustained, Specific Release of Paclitaxel to Irradiated Tumors. Cancer Research, 2010, 70, 4550-4559.	0.9	136
27	Efficacy of Skin-Directed Therapy for Cutaneous Metastases From Advanced Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 3144-3155.	1.6	131
28	Comparison of high-dose (86.4%Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU International, 2014, 114, 360-367.	2.5	125
29	Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 339-344.	0.8	122
30	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	12.8	109
31	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research, 2015, 75, 4688-4696.	0.9	105
32	Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. Journal of Urology, 2015, 194, 1624-1630.	0.4	93
33	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383.	1.9	93
34	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. Journal of Urology, 2016, 196, 405-411.	0.4	89
35	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	7.0	87
36	Racial Differences in Genomic Profiling of Prostate Cancer. New England Journal of Medicine, 2020, 383, 1083-1085.	27.0	87

#	ARTICLE	IF	CITATIONS
37	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	7.1	87
38	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. JAMA Oncology, 2021, 7, 544.	7.1	82
39	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	1.9	79
40	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncology, The, 2021, 22, 402-410.	10.7	79
41	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.8	77
42	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. Journal of Urology, 2017, 197, 662-668.	0.4	76
43	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clinical Cancer Research, 2019, 25, 6721-6730.	7.0	74
44	Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, 2022, 114, 1036-1039.	6.3	74
45	A Prospective Pilot Study of <sup>89</sup> Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2014, 191, 1439-1445.	0.4	73
46	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	1.9	72
47	American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy, 2017, 16, 1-12.	0.5	69
48	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	10.7	68
49	Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1881.	7.1	66
50	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	7.1	65
51	Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. European Urology, 2017, 71, 37-43.	1.9	64
52	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. JAMA Oncology, 2020, 6, 567.	7.1	64
53	Translational and clinical implications of the genetic landscape of prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 597-610.	27.6	63
54	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncology, 2020, 6, 735.	7.1	58

#	ARTICLE	IF	CITATIONS
55	Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. <i>Clinical Lung Cancer</i> , 2016, 17, 177-183.e2.	2.6	57
56	Are we there yet? Understanding androgen receptor signaling in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 47.	5.2	57
57	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , 2021, 12, 935.	12.8	56
58	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. <i>Nature Communications</i> , 2022, 13, 2559.	12.8	56
59	Short-term Androgen-Deprivation Therapy Improves Prostate Cancer-Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1012-1017.	0.8	55
60	Utility of FDG-PET in clinical neuroendocrine prostate cancer. <i>Prostate</i> , 2014, 74, 1153-1159.	2.3	55
61	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.8	55
62	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	1.9	55
63	Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e198-e208.	10.7	54
64	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	1.9	54
65	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	7.0	52
66	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	1.6	52
67	Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. <i>European Urology</i> , 2017, 72, 617-624.	1.9	50
68	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	4.4	50
69	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
70	Independent surgical validation of the new prostate cancer grade grouping system. <i>BJU International</i> , 2016, 118, 763-769.	2.5	48
71	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	7.1	46
72	Genomic biomarkers in prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 459-471.	1.4	46

#	ARTICLE	IF	CITATIONS
73	A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2013, 12, 428-433.	0.5	45
74	Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 435-440.	0.6	45
75	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 29.	5.2	45
76	Disparities in Castration-Resistant Prostate Cancer Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1101-1103.	1.6	43
77	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019, 380, 2070-2072.	27.0	42
78	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 69-76.	3.1	40
79	Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 357-363.	2.9	39
80	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
81	Patterns and Predictors of Amelioration of Genitourinary Toxicity After High-dose Intensity-modulated Radiation Therapy for Localized Prostate Cancer: Implications for Defining Postradiotherapy Urinary Toxicity. <i>European Urology</i> , 2013, 64, 931-938.	1.9	38
82	Challenges and opportunities in primary CNS lymphoma: A systematic review. <i>Radiotherapy and Oncology</i> , 2017, 122, 352-361.	0.6	38
83	Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. <i>European Urology</i> , 2019, 75, 1038-1040.	1.9	38
84	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	1.9	37
85	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	1.6	37
86	Racial disparities in prostate cancer among black men: epidemiology and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 397-402.	3.9	37
87	Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1067-1074.	0.8	35
88	Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3743-3750.	3.6	35
89	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	1.5	34
90	Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. <i>BJU International</i> , 2017, 120, E87-E95.	2.5	34

#	ARTICLE	IF	CITATIONS
91	Comparison of joint modeling and landmarking for dynamic prediction under an illness-death model. <i>Biometrical Journal</i> , 2017, 59, 1277-1300.	1.0	34
92	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	7.0	33
93	Current and emerging treatment options for nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2012, 5, 297.	2.0	32
94	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. <i>Spine Journal</i> , 2016, 16, 291-298.	1.3	32
95	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. <i>EJNMMI Research</i> , 2016, 6, 7.	2.5	32
96	Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	5.3	32
97	Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 52-58.	1.7	31
98	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?. <i>Radiology and Oncology</i> , 2014, 48, 56-61.	1.7	30
99	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 295-302.	3.9	30
100	Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable. <i>JAMA Network Open</i> , 2020, 3, e2015083.	5.9	30
101	Radiation-Induced Insufficiency Fractures After Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 620-634.	0.8	30
102	Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 696-705.	0.8	29
103	Mentorship Experiences of Early-Career Academic Radiation Oncologists in North America. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 732-740.	0.8	29
104	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	1.9	29
105	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018, 74, 99-106.	1.9	28
106	Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 355-362.	3.8	28
107	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	1.9	28
108	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	2.1	27

#	ARTICLE	IF	CITATIONS
109	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	7.1	27
110	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	1.6	26
111	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	3.8	26
112	Impact of FDG PET/CT on Delineation of the Gross Tumor Volume for Radiation Planning in Non-Small-Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2010, 35, 237-243.	1.3	25
113	Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2045-2049.	5.0	25
114	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2017, 3, 502-509.	3.1	25
115	Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature. <i>World Neurosurgery</i> , 2018, 109, e502-e509.	1.3	25
116	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 647-661.	3.9	25
117	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	2.5	24
118	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	7.0	24
119	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	3.5	24
120	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021, 154, 207-213.	0.6	24
121	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016, 2, 532-539.	3.1	23
122	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	5.4	23
123	Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. , 2022, 1, .		23
124	Time Course and Predictors for Cancer-Related Fatigue in a Series of Oropharyngeal Cancer Patients Treated with Chemoradiation Therapy. <i>Oncologist</i> , 2012, 17, 569-576.	3.7	22
125	Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. <i>Prostate</i> , 2017, 77, 154-163.	2.3	22
126	Thyroid Cancer Bone Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, e465-e471.	1.3	22



#	ARTICLE	IF	CITATIONS
127	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 419-428.	3.9	22
128	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018, 124, 1141-1149.	4.1	21
129	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 685-690.	5.4	21
130	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , 2020, 80, 146-152.	2.3	21
131	Clinical Applications of Molecular Biomarkers in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1550.	3.7	21
132	Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1176-1185.	0.8	21
133	Prognostic Importance of Gleason 7 Disease Among Patients Treated With External Beam Radiation Therapy for Prostate Cancer: Results of a Detailed Biopsy Core Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1254-1261.	0.8	20
134	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 628-636.	0.8	20
135	Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1030-1034.	0.8	20
136	A Comprehensive Assessment of <sup>68</sup> Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 567-572.	5.0	20
137	Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. <i>Neurosurgical Focus</i> , 2017, 42, E5.	2.3	19
138	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	2.1	19
139	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.6	19
140	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	1.2	19
141	Pan-cancer analysis of prognostic metastatic phenotypes. <i>International Journal of Cancer</i> , 2022, 150, 132-141.	5.1	19
142	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient "data Network Meta-analysis from the MARCAP Consortium. <i>European Urology</i> , 2022, 82, 106-114.	1.9	19
143	Radiation Therapy in the Treatment of Minor Salivary Gland Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 492-497.	1.3	18
144	Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	18

#	ARTICLE	IF	CITATIONS
145	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	1.9	18
146	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	1.9	18
147	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , 2020, 33, 1165-1171.	5.5	18
148	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	1.9	18
149	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	2.5	18
150	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1279-1285.	0.8	18
151	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	5.9	18
152	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. <i>European Urology</i> , 2018, 74, 529-531.	1.9	17
153	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	7.0	17
154	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. <i>JAMA Network Open</i> , 2019, 2, e187765.	5.9	17
155	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	1.2	17
156	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2163-2174.	4.1	17
157	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	3.9	17
158	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1596-1607.	5.5	17
159	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 523-531.	0.8	16
160	Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 462-467.	0.8	16
161	Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2914-2917.	1.6	16
162	Analysis of Outcomes Between Traditional Open versus Mini-Open Approach in Surgical Treatment of Spinal Metastasis. <i>World Neurosurgery</i> , 2019, 130, e467-e474.	1.3	16

#	ARTICLE	IF	CITATIONS
163	Adverse events in radiation oncology: A case series from wake up safe, the pediatric anesthesia quality improvement initiative. <i>Paediatric Anaesthesia</i> , 2019, 29, 265-270.	1.1	16
164	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , 2019, 86, 76-84.	2.0	16
165	<i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2595-2602.	7.0	16
166	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
167	Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 801-809.	4.9	15
168	The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 381-394.	0.4	15
169	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	2.2	15
170	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019, 36, 74.	2.5	15
171	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.	4.1	15
172	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	3.9	15
173	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	1.9	15
174	Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. <i>Cancer</i> , 2017, 123, 1635-1642.	4.1	14
175	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. <i>Journal of Clinical Oncology</i> , 2022, 40, 3172-3179.	1.6	14
176	Changes in prostate orientation due to removal of a Foley catheter. <i>Medical Physics</i> , 2018, 45, 1369-1378.	3.0	13
177	Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	3.0	13
178	A Video Decision Aid Improves Informed Decision Making in Patients With Advanced Cancer Considering Palliative Radiation Therapy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1048-1055.e2.	1.2	13
179	Thyroid Cancer Brain Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 544-549.	1.3	13
180	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. <i>Medical Oncology</i> , 2020, 37, 16.	2.5	13

#	ARTICLE	IF	CITATIONS
181	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	1.9	13
182	Applying <sup>89</sup> Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. <i>Molecular Pharmaceutics</i> , 2016, 13, 683-688.	4.6	12
183	Natural history of <sup>125</sup> I biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	2.5	12
184	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	5.2	12
185	Evolving Role of Stereotactic Body Radiation Therapy in the Management of Spine Metastases. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 167-189.	1.7	12
186	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. <i>European Urology Oncology</i> , 2022, 5, 304-313.	5.4	12
187	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	5.9	12
188	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	1.9	12
189	Race and Genetic Alterations in Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1650-1653.	3.0	12
190	TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results. <i>Cancer</i> , 2022, 128, 1513-1522.	4.1	12
191	Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. <i>Prostate</i> , 2015, 75, 175-182.	2.3	11
192	Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 770-777.	0.8	11
193	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 726-732.	0.8	11
194	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	2.9	11
195	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.8	11
196	Reporting of Racial Health Disparities Research: Are We Making Progress?. <i>Journal of Clinical Oncology</i> , 2022, 40, 8-11.	1.6	11
197	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	2.5	10
198	Predominance of Spinal Metastases Involving the Posterior Vertebral Body. <i>World Neurosurgery</i> , 2018, 119, e991-e996.	1.3	10

#	ARTICLE	IF	CITATIONS
199	Surgical Approach to Bone Metastases. <i>Current Osteoporosis Reports</i> , 2018, 16, 512-518.	3.6	10
200	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.8	10
201	Recommendations for Single-Fraction Radiation Therapy and Stereotactic Body Radiation Therapy in Palliative Treatment of Bone Metastases: A Statewide Practice Patterns Survey. <i>Practical Radiation Oncology</i> , 2019, 9, e541-e548.	2.1	10
202	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 621-627.	0.8	10
203	Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1179-1188.	0.8	10
204	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.	2.4	10
205	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. <i>Radiotherapy and Oncology</i> , 2021, 164, 104-114.	0.6	10
206	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 338-343.	0.8	9
207	Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 362-381.	0.8	9
208	Are we inadvertently widening the disparity gap in pursuit of precision oncology?. <i>British Journal of Cancer</i> , 2018, 119, 783-784.	6.4	9
209	Combination therapies in prostate cancer: proceed with caution. <i>Lancet Oncology</i> , The, 2019, 20, 321-323.	10.7	9
210	Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1477-1491.	2.5	9
211	Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. <i>Cancer</i> , 2020, 126, 3229-3236.	4.1	9
212	A transcriptomic model for homologous recombination deficiency in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 659-665.	3.9	9
213	Temporary organ displacement coupled with image-guided, intensity-modulated radiotherapy for paraspinal tumors. <i>Radiation Oncology</i> , 2013, 8, 150.	2.7	8
214	Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patients. <i>Brachytherapy</i> , 2013, 12, 389-392.	0.5	8
215	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. <i>Prostate</i> , 2017, 77, 1592-1600.	2.3	8
216	Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 513-515.	0.8	8

#	ARTICLE	IF	CITATIONS
217	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 599-610.	1.6	8
218	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 33-35.	0.8	8
219	Computed Tomography Myelosimulation Versus Magnetic Resonance Imaging Registration to Delineate the Spinal Cord During Spine Stereotactic Radiosurgery. <i>World Neurosurgery</i> , 2019, 122, e655-e666.	1.3	8
220	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020, 126, 1407-1412.	4.1	8
221	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	8
222	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion. <i>Medical Oncology</i> , 2019, 36, 27.	2.5	8
223	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. <i>BMC Cancer</i> , 2022, 22, 494.	2.6	8
224	Cabozantinib Resolves Bone Scans in Tumor-Na <sup>+</sup> ve Mice Harboring Skeletal Injuries. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00026.	1.4	7
225	Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2017, 19, 944-951.	2.6	7
226	External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. <i>Brachytherapy</i> , 2017, 16, 782-789.	0.5	7
227	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffeyâ€Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 1478-1488.	2.3	7
228	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.8	7
229	SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 618-620.	0.8	7
230	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020, 76, 875-887.	2.9	7
231	Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 899-902.	0.8	7
232	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. <i>Journal of Urology</i> , 2022, 207, 127-136.	0.4	7
233	Impact of Decipher on use of postâ€operative radiotherapy: Individual patient analysis of two prospective registries. <i>BJUI Compass</i> , 2021, 2, 267-274.	1.3	7
234	Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 942-950.	0.8	7

#	ARTICLE	IF	CITATIONS
235	Clinicogenomic characterization of prostate cancer liver metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 366-369.	3.9	7
236	Image-guided Radiation Therapy for Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 561-567.	1.3	6
237	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e25-542.e32.	1.6	6
238	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	5.4	6
239	Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 556-560.	0.8	6
240	Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 798-800.	0.8	6
241	BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 478-486.	0.8	6
242	Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. <i>Molecular Pharmaceutics</i> , 2020, 17, 1139-1147.	4.6	6
243	Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy. <i>European Urology Focus</i> , 2021, 7, 250-253.	3.1	6
244	Survival, fusion, and hardware failure after surgery for spinal metastatic disease. <i>Journal of Neurosurgery: Spine</i> , 2021, 34, 665-672.	1.7	6
245	Should brachytherapy be added to external beam radiotherapy for prostate cancer?. <i>Lancet Oncology</i> , 2022, 23, 23-25.	10.7	6
246	Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer. <i>Advances in Radiation Oncology</i> , 2016, 1, 300-309.	1.2	5
247	Genomic-adjusted radiation dose. <i>Lancet Oncology</i> , 2017, 18, e127.	10.7	5
248	Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 136, 585-593.	2.9	5
249	Population-Based Observational Studies in Oncology: Proceed With Caution. <i>Seminars in Radiation Oncology</i> , 2019, 29, 302-305.	2.2	5
250	Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2019, 86, E164-E172.	1.1	5
251	Prostate Cancer Transcriptomic Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 111-120.	1.6	5
252	Salvage Radiotherapy After Prostatectomy: Two Sides of the Coin. <i>European Urology</i> , 2016, 70, 758-759.	1.9	4

#	ARTICLE	IF	CITATIONS
253	ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. <i>Clinical Nuclear Medicine</i> , 2016, 41, 106-117.	1.3	4
254	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , 2017, 13, 154-157.	0.3	4
255	Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 155-162.	2.9	4
256	Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 6-12.	1.3	4
257	The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 139, 195-203.	2.9	4
258	Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 92-94.	0.8	4
259	Challenging the Norm: What Level of Evidence Is Necessary to Adopt Postprostatectomy Hypofractionated Radiation Therapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 297-298.	0.8	4
260	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2110950.	5.9	4
261	Contemporary Practice Patterns for Palliative Radiation Therapy of Bone Metastases: Impact of a Quality Improvement Project on Extended Fractionation. <i>Practical Radiation Oncology</i> , 2021, 11, e498-e505.	2.1	4
262	Photons, Protons, SBRT, Brachytherapy—What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1114-1121.	0.8	4
263	Drivers of racial disparities in prostate cancer trial enrollment. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 946-947.	3.9	4
264	End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2844-2845.	1.6	4
265	Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer. <i>Journal of Urology</i> , 2021, , 101097JU0000000000002256.	0.4	4
266	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. <i>European Urology Open Science</i> , 2022, 35, 74-78.	0.4	4
267	Quantitative Nodal Burden and Mortality Across Solid Cancers. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1003-1011.	6.3	4
268	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 278-289.	0.8	4
269	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	3.9	4
270	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. <i>Journal of Radiation Oncology</i> , 2013, 2, 285-291.	0.7	3



#	ARTICLE	IF	CITATIONS
271	Breast and Prostate Cancer: Lessons to Be Shared. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 263-268.	0.8	3
272	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018, 35, 21.	2.5	3
273	Genomics, bio specimens, and other biological data: Current status and future directions. <i>Medical Physics</i> , 2018, 45, e829-e833.	3.0	3
274	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	2.6	3
275	Tumor. <i>Operative Neurosurgery</i> , 2019, 17, S119-S152.	0.8	3
276	Tissue-based genomics. <i>Current Opinion in Urology</i> , 2019, 29, 598-604.	1.8	3
277	Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 382-390.	1.3	3
278	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	5.4	3
279	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. <i>World Journal of Clinical Oncology</i> , 2021, 12, 6-12.	2.3	3
280	Efficacy and Incontinence Rates After Urethroplasty for Radiation-induced Urethral Stenosis: A Systematic Review and Meta-analysis. <i>Urology</i> , 2021, 152, 109-116.	1.0	3
281	Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 965-967.	0.8	3
282	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	2.3	3
283	Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's Letter to the Editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. <i>Eur Urol</i> 2013;63:709-16. <i>European Urology</i> , 2013, 64, e29-e30.	1.9	2
284	To ProtecT Our Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1461.	7.1	2
285	Convergence of Genomic Instability and SChLAP1 : Weathering the Storm of Intraductal Carcinoma of the Prostate. <i>European Urology</i> , 2017, 72, 675-676.	1.9	2
286	Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>Eur Urol</i> 2018;73:156-65. <i>European Urology</i> , 2018, 73, e64-e65.	1.9	2
287	The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy. <i>European Urology</i> , 2019, 76, 596-598.	1.9	2
288	National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e1-353.e8.	1.6	2

#	ARTICLE	IF	CITATIONS
289	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2
290	Association or Causality: Does Whole Brain Proton Radiotherapy Not Impact IQ?. <i>Journal of Clinical Oncology</i> , 2020, 38, 2211-2212.	1.6	2
291	Evaluation of predictive model performance of an existing model in the presence of missing data. <i>Statistics in Medicine</i> , 2021, 40, 3477-3498.	1.6	2
292	Impact of Treating Physician on Radiation Therapy Related Severe Toxicities in Men with Prostate Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e292-e300.	2.1	2
293	Dose Escalation for Oligometastatic Disease: Is More Better?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 680-681.	0.8	2
294	MRI-Targeted Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 2109-2111.	27.0	2
295	Case Report: Role of an Iodinated Rectal Hydrogel Spacer, SpaceOAR Vue, in the Context of Low-Dose-Rate Prostate Brachytherapy, for Enhanced Post-Operative Contouring to Aid in Accurate Implant Evaluation and Dosimetry. <i>Frontiers in Oncology</i> , 2021, 11, 810955.	2.8	2
296	Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients. <i>BJU International</i> , 2022, , .	2.5	2
297	An Automated Algorithm to Improve the Precision of Basilar Artery Diameter Measurements Before and After Subarachnoid Hemorrhage-Induced Vasospasm in an Animal Model. <i>Neurosurgery</i> , 2010, 66, 137-143.	1.1	1
298	Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2677-2677.	1.6	1
299	Risk Stratification System and Pattern of Relapse in Patients Treated with Adjuvant Radiotherapy after Radical Prostatectomy. <i>Tumori</i> , 2016, 102, 323-329.	1.1	1
300	Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2018, 1, 323-324.	5.4	1
301	Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. <i>European Urology</i> , 2018, 74, 453-454.	1.9	1
302	Key considerations when reviewing subsequent primary cancers following radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e291.	10.7	1
303	What Are We Even Looking At?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 264-265.	0.8	1
304	Seeking Consistency in Guidelines: Level of Evidence, Trial Endpoints, and Personalized Recommendations. <i>Practical Radiation Oncology</i> , 2019, 9, 496-500.	2.1	1
305	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e96-e97.	1.9	1
306	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 152663.	2.3	1

#	ARTICLE	IF	CITATIONS
307	Why the UK Should Consider Gene Expression Testing in Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 149-155.	1.4	1
308	Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options. <i>Frontiers in Oncology</i> , 2020, 10, 1616.	2.8	1
309	Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 338-339.	0.8	1
310	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. <i>European Urology Focus</i> , 2020, 7, 797-806.	3.1	1
311	Radiotherapy for Advanced Prostate Cancer. , 2022, , 197-213.		1
312	Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
313	Locked-in: Listening to Save a Life. <i>Academic Medicine</i> , 2010, 85, 62.	1.6	0
314	Rebuttal to Dr. Stone. <i>Brachytherapy</i> , 2013, 12, 398-399.	0.5	0
315	Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. <i>Eur Urol</i> 2017;71:37â€“43. A Step Forward in the Era of Functional Imaging?. <i>European Urology</i> , 2017, 71, e123-e124.	1.9	0
316	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1075-1075.	0.4	0
317	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2017, 9, 695-699.	2.0	0
318	In Reply to Wilkins et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1597-1598.	0.8	0
319	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	1.2	0
320	Reply to J.R. Rider et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2696-2697.	1.6	0
321	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>Eur Urol</i> 2019;75:552â€“5. <i>European Urology</i> , 2019, 75, e133-e134.	1.9	0
322	Biology vs Access to Careâ€”Relative Contribution to Racial Disparities in Prostate Cancerâ€”In Reply. <i>JAMA Oncology</i> , 2019, 5, 1810.	7.1	0
323	Androgen deprivation therapy plus salvage radiotherapy after prostatectomy. <i>Lancet Oncology</i> , The, 2020, 21, e12.	10.7	0
324	Low Utilization of Androgen Deprivation Therapy Among Men Receiving Stereotactic Body Radiotherapy for Localized Prostate Cancer in the United States. <i>European Urology Oncology</i> , 2021, 4, 337-338.	5.4	0

#	ARTICLE	IF	CITATIONS
325	The Management of Prostate Cancer. Practical Guides in Radiation Oncology, 2021, , 3-23.	0.1	0
326	Importance of radiotherapy to the primary in metastatic hormone sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 929-930.	3.9	0
327	Reply to S. Sundar et al and S. HÃ¼cht et al. Journal of Clinical Oncology, 2021, 39, 2316-2317.	1.6	0
328	Exercise: A Treatment That Should Be Prescribed With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	0
329	Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial. European Urology, 2021, 80, 674-675.	1.9	0
330	Prostate SBRT Dose Escalation (9 Gyâ€”â€”5, 13.3 Gyâ€”â€”3, 24 Gyâ€”â€”1): Are We Making Progress?. International Journal of Radiation Oncology Biology Physics, 2021, 111, 110-112.	0.8	0
331	Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. , 2018, , 81-99.		0
332	Editorial Comment. Journal of Urology, 2020, 204, 89-90.	0.4	0
333	Racial Differences in Treatments and Toxicity in Patients With Nonâ€”Small-Cell Lung Cancer Treated With Thoracic Radiation Therapy. JCO Oncology Practice, 2022, , OP2100224.	2.9	0
334	Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative. International Journal of Radiation Oncology Biology Physics, 2022, 113, 316-319.	0.8	0